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A globally disseminated clone of
hyperinvasive M1T1 group A
Streptococcus (GAS) causes severe
infections, including necrotizing fasciitis.
LaRock et al. show that M1T1 GAS
circumvents immune defenses mediated
by human cathelicidin LL-37 by binding
this antimicrobial peptide through the
bacterial surface protein M1 and
sequestering it in a protein trap.
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The antimicrobial peptide LL-37 is generated upon
proteolytic cleavage of cathelicidin and limits
invading pathogens by directly targeting microbial
membranes as well as stimulating innate immune
cell function. However, some microbes evade LL-
37-mediated defense. Notably, group A Strepto-
coccus (GAS) strains belonging to the hypervirulent
M1T1 serogroup are more resistant to human LL-37
than other GAS serogroups. We show that the GAS
surface-associated M1 protein sequesters and neu-
tralizes LL-37 antimicrobial activity through its N-ter-
minal domain. M1 protein also binds the cathelicidin
precursor hCAP-18, preventing its proteolytic matu-
ration into antimicrobial forms. Exogenous M1 pro-
tein rescues M1-deficient GAS from killing by neutro-
phils and within neutrophil extracellular traps and
neutralizes LL-37 chemotactic properties. M1 also
binds murine cathelicidin, and its virulence contribu-
tion in a murine model of necrotizing skin infection is
largely driven by its ability to neutralize this host de-
fense peptide. Thus, cathelicidin resistance is essen-
tial for the pathogenesis of hyperinvasive M1T1 GAS.
INTRODUCTION
Cathelicidins are cationic antimicrobial peptides produced by
leukocytes and epithelial cells that provide a critical first line of
defense against microbial invasion (Wong et al., 2013; Nizet
et al., 2001). Cathelicidin expression is strongly induced during
infection and injury (Dorschner et al., 2001), initially as a full-
length protein that lacks antimicrobial activity (Zaiou et al.,
2003). Neutrophil proteinase-3 and keratinocyte kallikreins pro-
cess cathelicidin to liberate antimicrobial peptides derived
from its carboxyl terminus (Murakami et al., 2004; Sørensen
et al., 2001; Yamasaki et al., 2006). Some cathelicidin peptides,Cell Hostthe best characterized being human LL-37, also function as
signaling molecules to stimulate inflammation (Yamasaki et al.,
2007), production of other antimicrobials (Alalwani et al., 2010),
chemotaxis (De Yang et al., 2000), and formation of neutrophil
extracellular traps (NETs) (Neumann et al., 2014).
Streptococcus pyogenes (group A Streptococcus; GAS) is a
leading human pathogen, associated with hundreds of millions
of pharyngeal and skin infections yearly (Carapetis et al.,
2005). GAS are commonly classified on the basis of the antigen-
ically variable surface M protein, an important virulence factor
encoded by the emm gene, of which >200 genotypes have
been characterized (McMillan et al., 2013). The past several de-
cades have witnessed an increase in severe invasive forms of
GAS infection such as necrotizing fasciitis and streptococcal
toxic shock syndrome, largely attributable to the rise of a single
globally disseminated hyperinvasive M1T1 (emm1) clone (Aziz
and Kotb, 2008; Walker et al., 2014). The ability of M1T1 GAS
to produce serious infections defines an intrinsic resistance to
innate immune defenses that normally restrict GAS invasiveness.
Indeed, compared to other serotype strains,M1T1 serotypeGAS
are highly resistant to the cathelicidin-derived peptide LL-37 and
to NETs (Lauth et al., 2009), in which cathelicidin is highly abun-
dant. Here, we sought to examine the molecular mechanism
underlying the cathelicidin resistance of M1T1 GAS and the
extent to which it contributes to the increased virulence of these
isolates.RESULTS
GAS Is Protected by M1 Protein Binding of LL-37
M1T1 GAS lacking M1 protein are more susceptible to killing by
human cathelicidin LL-37 (Lauth et al., 2009). M protein is the
most abundant protein on the GAS surface (Severin et al.,
2007), extending from the bacterial cell surface in the form of
hair-like fimbriae (Phillips et al., 1981). One important category
of streptococcal antimicrobial peptide resistance mechanisms
involves electrostatic repulsion of the cationic peptides away
from the bacterial surface (LaRock and Nizet, 2015). However,
we found by flow cytometry that M1T1 GAS bound significantly
more LL-37 than isogenic Demm1 mutant bacteria (Figures 1A& Microbe 18, 471–477, October 14, 2015 ª2015 Elsevier Inc. 471
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Figure 1. GAS Is Protected by M1 Protein Binding of LL-37
(A–C) Mid-log WT or Demm1M1T1 GAS were incubated with 2 mM LL-37 and propidium iodide. (A and B) FACS detection of LL-37 on the bacterial surface with
anti-LL-37 antibody indicates that Demm1 GAS binds significantly less LL-37 than WT GAS. (C) Flow cytometric quantification of cells staining positive for
propidium iodide shows significantly more Demm1 GAS have disrupted cell walls compared to WT. RU, relative units.
(D) Dot blot of pull-down analysis with His-tagged recombinant M protein and LL-37, detected by western blot with anti-LL-37 antibody.
(E) MIC assay of LL-37-susceptible Demm1 GAS with recombinant M protein to increase resistance.
Means ± SD (n = 3) are shown. *p < 0.05. Figures are representative of at least three independent experiments.and 1B). Despite binding more cathelicidin, fewer of the M1-
expressing GAS were killed as quantified by propidium iodide
uptake (Figure 1C). These results indicate that M1 does not
repel LL-37, yet still protects GAS from killing by the antimicro-
bial peptide.
We hypothesized that M1 protein could provide an alternative
binding site to entrap LL-37 away from the bacterial membrane,
thereby preserving bacterial cell integrity. Through pull-down
analysis, we found that recombinant M1 protein directly bound
LL-37 (Figure 1D). Further mapping of this interaction using
M1-derived fragments revealed that the region most distal to
the bacterial surface, carrying the A region and B repeats
(M1AB), was sufficient for binding (Figure 1D). The addition of re-
combinant M1 or M1AB to cultures of Demm1 GAS reversed the
LL-37 susceptibility phenotype of the mutant (Figure 1E),
whereas no protective effect was seen with recombinant M pro-
tein from less invasive M49 serotype GAS (Figure 1E). This
suggests that the linkage of M1 protein to LL-37 resistance is in-
dependent of cell alterations due to M1 deletion but rather de-
rives from direct sequestration of LL-37 by M1 protein.
M1 Binds Immature Cathelicidin to Block Antimicrobial
Peptide Generation
To examinewhetherM1 sequestration of LL-37 is functional in an
infection context, we performed pull-down analysis using whole
lysates from neutrophils, the major producers of the human
defense peptide (Sørensen et al., 2001). Surprisingly, the major
cathelicidin form detected was uncleaved hCAP18 (Figure 2A).
This was confirmed by flow cytometric analysis, where recombi-
nant hCAP18 bound the GAS surface in an M1-dependent
manner (Figures 2B and 2C). Surface plasmon resonance
confirmed a high differential affinity of M1 protein to both LL-
37 and hCAP-18. Compared to M49 protein, calculated diffusion
constant (Kd) values for M1 indicated 53-fold stronger binding to
LL-37 (1.18 mM versus 62.67 mM) and 10-fold stronger binding to
hCAP-18 (0.92 mM versus 9.07 mM) (Figure 2D).
In addition to binding LL-37 and hCAP18, M1 also bound the
peptides KR-20 and KR-12 (Figure 2E), the most active pro-
cessed forms of cathelicidin expressed by keratinocytes in hu-
man skin (Yamasaki et al., 2006). This activity was not limited
to human cathelicidin, as the active murine form, mCRAMP,472 Cell Host & Microbe 18, 471–477, October 14, 2015 ª2015 Elsevwas also bound (Figure 2E). Consistent with binding cathelicidin
family peptides, M1 protected GAS from killing by KR-20, KR-12,
LL-37, and mCRAMP, but not from the similarly charged defen-
sin-family peptides a-defensin-1 (hNP1), b-defensin-1 (hBD1),
b-defensin-2 (hBD2), and b-defensin-3 (hBD3) (Figure 2F).
Unprocessed hCAP18 lacked antimicrobial activity (Figure 2F),
consistent with previous reports that only the cleavage products
are active (Zaiou et al., 2003). Antimicrobial binding and killing
are coupled properties of its cationic charge (Lai and Gallo,
2009), so it was surprising that immature cathelicidin interacted
with the bacterium without toxicity. M1 protein binding of imma-
ture cathelicidin suggested the possibility that the proteolytic
maturation of cathelicidin into antimicrobial peptides could be
altered. Indeed, M1 inhibited hCAP18 processing by the neutro-
phil proteinase-3 (PRTN3) (Sørensen et al., 2001) and the kerati-
nocyte kallikrein-5 (KLK5) (Yamasaki et al., 2006) (Figure 2G). M1
did not inhibit PRTN3 or KLK5 processing of another substrate
(Figure 2H), indicating that M1 is not acting broadly as a protease
inhibitor. Instead, this suggests that hCAP18 is protected from
proteolytic activation when complexed with M1, allowing GAS
to inhibit the generation of antimicrobial peptides.
Multipronged Innate Immune Cell Subversion by M1
through Cathelicidin Sequestration
M1 protein is reported to promote GAS survival during interac-
tions with neutrophils (Lauth et al., 2009) and macrophages
(Hertze´n et al., 2010), two of the major producers of cathelicidin
(LaRock andNizet, 2015).We found that wild-type (WT) GASwas
more resistant to human neutrophil killing than the Demm1
mutant (Figure 3A) and survived better within NETs (Figure 3B).
However, the attenuated survival of the Demm1 mutant incu-
bated with neutrophils or NETs was reversed by the addition of
exogenous recombinant M1 protein (Figures 3A and 3B). In
neither instance did the addition of rM1 promote further survival
of WT GAS, indicating that the native expression of M1 is suffi-
cient to afford complete protection against neutrophil-expressed
cathelicidin. These findings indicate that M1 does not have to be
expressed on the bacterial surface to be protective, consistent
with the molecular mechanism of cathelicidin sequestration.
To determine whether M1 inhibition of cathelicidin con-
tributes to GAS resistance to macrophage killing, we infectedier Inc.




Figure 2. M1 Binds Immature Cathelicidin to Block Antimicrobial Peptide Generation
(A) Interaction between rM1 and cathelicidin from neutrophil lysate by pull-down analysis and western blot using anti-LL-37 antibody.
(B andC) In (B), flow cytometric detection of recombinant hCAP18 on the bacterial surface with anti-LL-37 antibody indicates thatDemm1GAS binds significantly
less hCAP18 than WT GAS, quantified in (C).
(D) Representative sensorgrams from surface plasmon resonance analysis of M1 or M49 protein binding to immobilized LL-37 or hCAP18. Gray scale indicates
concentration of M protein analyte in 2-fold dilutions starting from 80 mM (black) to 78.125 nM (lightest gray) at 5 mM (M1-LL-37), 80 mM (M49-LL-37), 1.25 mM (M1-
hCAP18), or 80 mM (M49-hCAP18).
(E) Pull-down analysis with rM1 as bait for full-length (hCAP18) or truncated (LL-37, KR-20, KR-12, mCRAMP) forms as shown by dot blot probed with anti-LL-37
antibody.
(F) Resistance of WT and Demm1 GAS to full-length cathelicidin and the antimicrobial peptides from the cathelicidin (LL-37, KR-20, KR-12, mCRAMP) and
defensin (hNP1, hBD1, hBD2, hBD3) families.
(G) Cleavage of recombinant hCAP18 by increasing amounts of PRTN3 or KLK5 (one, two, or five enzymatic units) in the presence or absence of rM1, as visualized
by western blot with anti-LL-37 antibody.
(H) Enzymatic activity of PRTN3 or KLK5 in the presence of rM1. ns, not significant.
Figures are representative of at least three independent experiments.macrophages derived from WT (C57BL/6) and cathelicidin-defi-
cient (CRAMP/) mice. Compared to the WT GAS, the Demm1
mutant had markedly attenuated survival in WT macrophages
but similar growth in CRAMP/macrophages (Figure 3C). In hu-
man cells, vitamin D strongly induces cathelicidin expression (Liu
et al., 2006). We found that Demm1GAS became hyper-suscep-
tible to killing by human THP-1 macrophages when cathelicidin
expression was amplified by vitamin D treatment (Figure 3D).
Cathelicidin is also abundantly produced by mast cells and
contributed to killing of the cathelicidin-susceptible serotype
M49 GAS in the mouse model (Di Nardo et al., 2008). We found
that M1 promoted GAS resistance to killing by murine mast cells
in a cathelicidin-dependent manner (Figure 3E).
In addition to microbial killing, cathelicidin cleavage products
further amplify the innate immune response by stimulating
chemotaxis of neutrophils to the foci of infection (De Yang
et al., 2000). We tested the effect of M1 protein on LL-37-medi-
ated chemotaxis using a Transwell system. LL-37 and the posi-Cell Hosttive control N-formyl-Met-Leu-Phe (fMLP) both stimulated
robust chemotaxis of neutrophils (Figure 3F). rM1 did not stimu-
late or inhibit chemotaxis on its own but did inhibit LL-37-
mediated migration (Figure 3G). Chemotaxis inhibition by the
M1 protein further indicates that interfering with cathelicidin
function is a virulence strategy that can promote bacterial sur-
vival by several modalities.
GAS Inhibition of Cathelicidin Permits Invasive Infection
Our in vitro analyses suggest that M1 protein binding of catheli-
cidin could promote GAS innate immune resistance in several
manners. To examine the contribution of cathelicidin sequestra-
tion by the M1 protein on GAS in vivo, we used a subcutaneous
wound infection model with C57BL/6 and CRAMP/ littermate
mice and followed the development of necrotic skin ulcers at
the site of GAS inoculation. In WT mice, WT M1 GAS produced
larger lesions than the Demm1 mutant, consistent with the
known virulence role of the M1 protein (Figures 4A and 4B).& Microbe 18, 471–477, October 14, 2015 ª2015 Elsevier Inc. 473
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Figure 3. Multipronged Innate Immune Cell Subversion by M1 through Cathelicidin Sequestration
(A and B) Human neutrophils were infected with GAS for 2 hr, (A) untreated, or (B) after 4 hr pretreatment with 25 nM phorbol 12-myristate 13-acetate to induce
NET formation.
(C–E) Cells derived from C57BL/6 or CRAMP/mice (C and E) or culture (D) were primed with 100 ng/ml lipopolysaccharide (C and E) or 20 nM vitamin D (active
1,25D3 form) (D) for 18 hr and then infected with WT M1 or Demm1 GAS for 2 hr.
(F and G) Human neutrophils were seeded in the upper chamber of a 3-mmTranswell with LL-37, fMLP, and/or recombinant M1 protein in the lower chamber, and
migration was measured by myeloperoxidase activity in the lower chamber after 1 hr.
Means ± SD (n = 3) are shown. *p < 0.05; ns, not significant. Figures are representative of at least three independent experiments.Remarkably, in CRAMP-deficient/ mice, Demm1 GAS was
able to form lesions of size comparable to WT GAS (Figures 4A
and 4B). This reversal of attenuation in CRAMP/ mice was
not seen for Demm49 GAS (Figures 4E and 4F), which agrees
with the observation that M1, but not M49, binds and inhibits
CRAMP. Interestingly, M49 GAS formed larger lesions in
CRAMP/ mice (Figures 4E and 4F), whereas M1 GAS pro-
duced similar sized lesions in WT and cathelicidin-deficient
animals (Figures 4A and 4B), suggesting that the M1 protein
effectively counteracts the cathelicidin contribution to innate de-
fense in this localized GAS infection model.
When bacteria were harvested for colony-forming-unit (CFU)
enumeration 72 hr after infection, the Demm1 GAS recovered
from WT mice were comparable to the initial inoculum, whereas
WT M1 GAS had proliferated over one order of magnitude (Fig-
ure 4C). Consistent with the lesion size data, in vivo proliferation
of Demm1 GAS was restored to WT levels in CRAMP/ mice
(Figure 4C). Together, these data suggest that, while M proteins
havemany virulence functions, cathelicidin inhibition is themajor
virulence contribution of the M1 protein in this model. Although
Demm49 was similarly attenuated in WT mice, its growth was
not similarly restored in CRAMP/ mice (Figure 4G). This indi-
cates that the attenuation reversal of Demm1 is specifically
due to the ability of M1 to inhibit cathelicidin and not a more
generalized immune defect of CRAMP/ mice. Highlighting
these differences in another way, the growth index of WT M1
GAS was greater than the isogenic Demm1 mutant only in WT
mice where cathelicidin is expressed (Figure 4D), whereas M49
contribution to virulence was independent of host cathelicidin
expression (Figure 4H).474 Cell Host & Microbe 18, 471–477, October 14, 2015 ª2015 ElsevDISCUSSION
Antimicrobial peptides provide a countermeasure against bacte-
ria that is conserved across all kingdoms of life. Mice lacking
cathelicidin antimicrobial peptides aremore susceptible to infec-
tion (Nizet et al., 2001), and qualitative defects in cathelicidin
expression or activity play a role in the increased infection rates
of humans with cystic fibrosis (Goldman et al., 1997), morbus
Kostmann (Pu¨tsep et al., 2002), and chronic vitamin D deficiency
(Liu et al., 2006). Conversely, dysregulated and excessive levels
of cathelicidin expression can be damaging to the host and a
driver of diseases such as rosacea (Yamasaki et al., 2007), hidra-
denitis suppurativa (Emelianov et al., 2012), and cigarette-
smoke-associated chronic obstructive pulmonary disease (Sun
et al., 2014). Cathelicidin expression may be limited because of
these proinflammatory liabilities to levels for which resistance
by pathogens is possible.
Our results show that one pathogenic bacterial clone, hyper-
virulent M1T1 GAS, has developed high-level cathelicidin
resistance. Indeed, M1 GAS produced equivalent lesions and
bacterial loads in WT and CRAMP/ mice, indicating that it is
fully resistant to cathelicidin in vivo, which has provided it a sig-
nificant virulence benefit. In contrast, M49 GAS has not evolved
high-level resistance to cathelicidin. It causes more severe dis-
ease in CRAMP/mice than WT, as is true for other pathogens
tested (Bergman et al., 2006; Chromek et al., 2006; Huang et al.,
2007; Kovach et al., 2012; Nizet et al., 2001). Therefore physio-
logical levels of cathelicidin are restrictive for other GAS strains,
but M1 protein allows the resistance of hypervirulent M1T1 GAS
to levels above those achieved in vivo.ier Inc.
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Figure 4. GAS Inhibition of Cathelicidin Permits Invasive Infection
(A–H) Mice were infected subcutaneously with the GAS strains indicated for 72 hr.
(A and E) GAS mutant for M protein (Demm1; Demm49) formed smaller lesions in cathelicidin-expressing mice (WT, C57BL/6), but the capacity to form lesions
was restored for Demm1 in CRAMP/ mice.
(B and F) Average lesion sizes enumerated in (B) and (F) demonstrate that these differences are significant.
(C and G) Lesions were excised and homogenized, and CFUs were enumerated by dilution plating.
(D and H) Growth index, measuring growth of WT bacteria compared to emm mutants, showed WT GAS outcompeting mutant bacteria 10-fold, except in
CRAMP/ mice, where M1 and M1 Demm1 grew comparably.
Means ± SD (n = 5) are shown. *p < 0.05; ns, not significant. Figures are representative of at least three independent experiments.M1 protein provides a multifaceted cathelicidin resistance
advantage to GAS. Specifically, M1 directly binds LL-37 and
other cathelicidin derivatives. This sequestration is sufficient
to double or quadruple the concentration of these peptides
required to kill the bacterium. Resistance to these peptides
carries over to the interaction of GAS with cathelicidin-express-
ing immune cells such as macrophages, mast cells, and neutro-
phils. Moreover, M1 protein also inhibits cathelicidin-induced
chemotaxis, further promoting GAS evasion of the immune
response.
Interestingly, M1 protein bound the uncleaved storage form of
cathelicidin in addition to the mature antimicrobial peptides.
However, because uncleaved cathelicidin and its activating pro-
teases can be found extracellularly (Sørensen et al., 1999), this
may represent another facet of the antimicrobial evasion strat-
egy of GAS. Cathelicidin bound by M1 protein was no longer
cleaved by activating proteases, maintaining it in a non-antimi-
crobial form. By acting upstream of the activation of cathelicidin,
GAS is able to pre-empt bacterial killing. In contrast to this two-
pronged mechanism we describe for M1 protein, other patho-
gens are only known to resist antimicrobial peptides through
sequestration, degradation, and masking or altering their cell
surface (LaRock and Nizet, 2015). Identification of additional
antimicrobial peptide-binding virulence factors may reveal this
mechanism to be prevalent, with the microbe agnostic to the
cleavage state of cathelicidin. Understanding the molecular
mechanisms by which microbial pathogens control cathelicidin
may provide targets to sensitize the pathogen to innate immune
clearance or, conversely, strategies to co-opt the same catheli-Cell Hostcidin inhibitors for use in immune diseases such as rosacea,
where cathelicidin overexpression is implicated.
EXPERIMENTAL PROCEDURES
Bacterial Culture
GAS strains M1T1 5448 and M49 NZ131 and their isogenic Demm mutants
have been previously described (Lauth et al., 2009). GAS strains were routinely
propagated at 37C on Todd-Hewitt broth (THB, Difco). GAS strains grown
overnight at 37C were diluted 1:40 into THB and grown statically at 37C to
an optical density 600 (OD600) of 0.400. Bacteria were washed in PBS and
diluted to a multiplicity of infection (MOI) of 10 for in vitro experiments. For min-
imum inhibitory concentration (MIC) assays, 23 105 bacteria were diluted into
serum-free DMEM containing phenol red and 10% THB, and the minimum
antimicrobial concentration that prevented growth of bacteria after a 24-hr
incubation was noted.
Protein Protocols
Expression and purification of rM1, rM1AB, rM1BC1, and rM49 has been
described previously (Lauth et al., 2009; Macheboeuf et al., 2011; McNamara
et al., 2008). The cathelicidin peptides LL-37, KR-20, KR-12, and mCRAMP
were made by de novo synthesis (Anaspec). The full coding sequence of hu-
man cathelicidin hCAP18was chemically synthesized (GenScript) and inserted
into the expression vector pET28a. The protein was expressed using standard
protocols and native purified by standard protocols in buffer made of 10 mM
imidazole, 0.3 M NaCl, 20 mM Na2HPO4 (pH 7.4), using cobalt chelate resin
(Thermo Fisher). Pull-downs were performed by fixing 5 mg recombinant
6xHis-tagged M1 protein onto cobalt chelate resin as bait (Thermo Fisher),
incubating with 5 mg cathelicidin and eluting with 100 mM imidazole, with three
washes between each step, with the same buffer at all steps (5 mM imidazole,
100 mM NaCl, 20 mM Tris [pH 7]). Samples were run by SDS-PAGE or dot
blotted directly onto polyvinylidene fluoride (PVDF) and immunoblotted for
LL-37 or CRAMP (Santa Cruz Biotechnology) with IR-conjugated secondary& Microbe 18, 471–477, October 14, 2015 ª2015 Elsevier Inc. 475
antibodies (LI-COR Biosciences), and visualized on an Odyssey infrared scan-
ner (LI-CORBiosciences). Proteolysis assays were carried out using 1 mg cath-
elicidin and M protein, with the indicated amount of PRTN3 or KLK5 (VWR),
and visualized by western blot; or VLD-pNA or AAPV-pNA (Enzo) was added
and hydrolysis monitored by an increase in optical density 405 (OD405)
(Spectramax).
Binding kinetics were analyzed by surface plasmon resonance using
the Biacore T100 (GE Healthcare). A C1 sensor chip was activated with
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide.
LL-37 or CAP18 in 10 mM sodium acetate (pH 5.5) was injected at
10 ml/min for 420 s. Remaining reactive groups were quenched using 1M etha-
nolamine. In parallel, a reference flow cell was activated and quenched without
ligand immobilization. M proteins in PBS, 0.005% Tween-20, were injected at
30 ml/min for 75 s. After at least 180 s of dissociation, the chip was regenerated
using 10mMglycine-HCl (pH 1.7). Reference and buffer-only values were sub-
tracted, and kinetic analysis was performed using Biacore Evalution Software
(GE Healthcare). Kd values were calculated using a steady-state affinity model.
Each experiment was performed twice with similar results.
Cell Culture
Cell lines were cultured in RPMI (GIBCO) containing 10% fetal bovine serum
(GIBCO) at 37C in 5% CO2 and seeded at 2 3 10
5 cells per milliliter. THP-1
cells were originally obtained from the ATCC and treated with phorbol 12-myr-
istate 13-acetate (Sigma) 72 hr pre-infection.Murinemacrophages, mast cells,
and neutrophils were differentiated by standard protocols from the femur ex-
udates of WT C57BL/6 or isogenic CRAMP/mice (Nizet et al., 2001). Human
neutrophils were isolated from healthy donors using PolyMorphPrep (Axis-
Shield) in accordance with the University of California, San Diego, (UCSD)
Human Research Protections Program. For total killing, the cells were lysed
with 0.05% Triton X-100 for 10 min before dilution plating for CFUs. In intracel-
lular survival experiments, the media were replaced with RPMI containing
100 mg/ml gentamicin 30 min before lysis and plating. For NET assays, neutro-
phils were stimulated with 25 nM phorbol 12-myristate 13-acetate (Sigma) 4 hr
pre-infection. For chemotaxis assays, 1 3 106 cells were seeded in the upper
chambers of 3-mm-pore Transwell inserts (Corning Life Sciences), with the
indicated concentrations of fMLP (Sigma), LL-37 (Anaspec), and rM1 in
RPMI in the lower chambers. Following incubation for 1 hr at 37C with 5%
CO2, Transwell inserts were removed and cells migrated to the lower chamber
were lysed via addition of 0.1% Triton X-100. To quantify chemotaxis, the
chromogenic elastase substrate N-methoxysuccinyl-Ala-Ala-Pro-Val p-nitroa-
nilide was added to lysate samples (1 mM final); following a 30-min incubation
at room temperature, absorbance at 405 nm was measured using a Spectra-
Max plate reader (Molecular Devices).
Flow Cytometry
For flow cytometery, samples were prepared by growing GAS using the stan-
dard protocol followed by a 30-min incubation with 2 mM LL-37. Cells were
washed, blocked 30 min with 10% BSA (Sigma), probed with anti-LL-37
(Santa Cruz Biotechnology) and Alexa Fluor-dye conjugated secondary anti-
body (Invitrogen), and run on a FACSCalibur system (BD Biosciences).
Bacterial cells were gated according to forward and side scatter and the fluo-
rescence intensity measured for a total of 50,000 bacteria. Negative controls
of bacteria untreated by LL-37, primary antibody, or secondary antibody
were included, and data were analyzed with FlowJo (Tree Star). Cell perme-
ability was monitored in parallel by staining with 10 mg/ml propidium iodide.
Animal Experiments
The UCSD Institutional Animal Care and Use Committee approved all use and
procedures. Eight- to ten-week-old C57BL/6 and littermate CRAMP/ mice
were infected subcutaneously with 1 3 108 (M1) or 6 3 108 (M49) CFUs in
100 ml of PBS. Lesions were imaged daily and surface area quantified using
ImageJ software. At 72 hr, lesions were excised, homogenized, and dilution
plated onto THB plates for enumeration of bacterial CFUs.
Statistical Analysis
Statistical significance (*p < 0.05) was calculated by unpaired Student’s t test
(GraphPad Prism), unless otherwise indicated. Data are representative of at
least three independent experiments.476 Cell Host & Microbe 18, 471–477, October 14, 2015 ª2015 ElsevAUTHOR CONTRIBUTIONS
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